<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03938571</url>
  </required_header>
  <id_info>
    <org_study_id>2016/133</org_study_id>
    <nct_id>NCT03938571</nct_id>
  </id_info>
  <brief_title>Standard Duodenal Switch vs. Single Anastomosis Duodeno-Ileostomy Duodenal Switch</brief_title>
  <official_title>Torsby I Trial: A Prospectively Randomized Study on Standard Duodenal Switch vs. Single Anastomosis Duodeno-ileostomy Duodenal Switch</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Värmland County Council, Sweden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Värmland County Council, Sweden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the Torsby I Trial is to identify differences and similarities between a standard
      duodenal switch (DS) and a single-anastomosis duodeno-ileostomy (SADI) regarding effect on
      weight, comorbidities and malnutrition.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Anticipated">January 2029</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of weight (kg)</measure>
    <time_frame>January 2024 (5 yr follow-up) and january 2029 (10 yr follow-up)</time_frame>
    <description>Change of weight in kg with calculation of the relative weight-loss under the follow-up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Early complications</measure>
    <time_frame>Up to 10 years after operation</time_frame>
    <description>Rate of minor and major complications</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alterations in comorbidities (hypertension)</measure>
    <time_frame>January 2021 (2 yr follow-up), january 2024 (5 yr follow-up), january 2029 (10 yr follow-up)</time_frame>
    <description>Changes of the metabolic profile (hypertension).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alterations in comorbidities (diabetes)</measure>
    <time_frame>January 2021 (2 yr follow-up), january 2024 (5 yr follow-up), january 2029 (10 yr follow-up)</time_frame>
    <description>Changes of the metabolic profile (diabetes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alterations in comorbidities (sleeping apnea)</measure>
    <time_frame>January 2021 (2 yr follow-up), january 2024 (5 yr follow-up), january 2029 (10 yr follow-up)</time_frame>
    <description>Changes of the metabolic profile (sleeping apnea)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alterations in comorbidities (hyperlipideamia)</measure>
    <time_frame>January 2021 (2 yr follow-up), january 2024 (5 yr follow-up), january 2029 (10 yr follow-up)</time_frame>
    <description>Changes of the metabolic profile (hyperlipidemia)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of malnutrition (protein)</measure>
    <time_frame>January 2021 (2 yr follow-up), january 2024 (5 yr follow-up), january 2029 (10 yr follow-up)</time_frame>
    <description>Changes of levels of protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of malnutrition (vitamin A)</measure>
    <time_frame>January 2021 (2 yr follow-up), january 2024 (5 yr follow-up), january 2029 (10 yr follow-up)</time_frame>
    <description>Changes of levels of vitamin A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of malnutrition (vitamin D)</measure>
    <time_frame>January 2021 (2 yr follow-up), january 2024 (5 yr follow-up), january 2029 (10 yr follow-up)</time_frame>
    <description>Changes of levels of vitamin D</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of malnutrition (vitamin B12)</measure>
    <time_frame>January 2021 (2 yr follow-up), january 2024 (5 yr follow-up), january 2029 (10 yr follow-up)</time_frame>
    <description>Changes of levels of vitamin B12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of malnutrition (vitamin B6)</measure>
    <time_frame>January 2021 (2 yr follow-up), january 2024 (5 yr follow-up), january 2029 (10 yr follow-up)</time_frame>
    <description>Changes of levels of vitamin B6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of malnutrition (vitamin B1)</measure>
    <time_frame>January 2021 (2 yr follow-up), january 2024 (5 yr follow-up), january 2029 (10 yr follow-up)</time_frame>
    <description>Changes of levels of vitamin B1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of malnutrition (vitamin E)</measure>
    <time_frame>January 2021 (2 yr follow-up), january 2024 (5 yr follow-up), january 2029 (10 yr follow-up)</time_frame>
    <description>Changes of levels of vitamin E</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of malnutrition (calcium)</measure>
    <time_frame>January 2021 (2 yr follow-up), january 2024 (5 yr follow-up), january 2029 (10 yr follow-up)</time_frame>
    <description>Changes of levels of calcium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late minor complications</measure>
    <time_frame>January 2021 (2 yr follow-up), january 2024 (5 yr follow-up), january 2029 (10 yr follow-up)</time_frame>
    <description>Rate of minor complications (Clavien Dindo &lt; IIIB)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late major complications</measure>
    <time_frame>January 2021 (2 yr follow-up), january 2024 (5 yr follow-up), january 2029 (10 yr follow-up)</time_frame>
    <description>Rate of major complications (Clavien Dindo &gt; and = IIIB)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Obesity</condition>
  <condition>Surgery</condition>
  <condition>Metabolic Syndrome</condition>
  <condition>Malnutrition</condition>
  <arm_group>
    <arm_group_label>Standard DS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard duodenal switch:
Sleeve gastrectomy over a 35 Fr bougie
Division of the duodenum 2-3 cm distally of the pylorus
Measurement of the small bowel. 100 cm common channel. 150 cm alimentary limb.
Duodenoileostomy completely handsewn with 250 cm distance to the ileocecal valve.
Entero-entero-anastomosis linear stapled and handsewn.
Division between the two anastomosis.
Closure of the mesenteric defects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SADI-DS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Duodenal switch with Single anastomosis duodeno-ileostomy:
Sleeve gastrectomy over a 35 Fr bougie
Division of the duodenum 2-3 cm distally of the pylorus
Measurement of the small bowel. 250 cm alimentary limb/common channel.
Duodenoileostomy completely handsewn with 250 cm distance to the ileocecal valve.
Closure of the mesenteric defects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Duodenal Switch</intervention_name>
    <arm_group_label>SADI-DS</arm_group_label>
    <arm_group_label>Standard DS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI over 45

          -  Ability to understand the legal background of a study

        Exclusion Criteria:

          -  Previous bariatric or anti-reflux surgery

          -  Drug-abuse

          -  Inflammatory bowel disease

          -  Complex psychiatric situation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bengt Hansske, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Consultant</affiliation>
  </overall_official>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>March 11, 2019</study_first_submitted>
  <study_first_submitted_qc>May 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2019</study_first_posted>
  <last_update_submitted>May 2, 2019</last_update_submitted>
  <last_update_submitted_qc>May 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Malnutrition</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

